<DOC>
	<DOCNO>NCT02066402</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety Tedizolid 200mg daily ( intra venous ) I.V . oral 6-day treatment compare Linezolid 600mg twice daily I.V . oral 10-day treatment Acute Bacterial Skin skin structure infection ( ABSSSI ) .This double-blind , randomize , active control , 7-10days treatment subject .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Oral 6-Day Tedizolid Phosphate vs. Intravenous Oral 10-Day Linezolid Patients With Acute Bacterial Skin Skin Structure Infection ( ABSSSI )</brief_title>
	<detailed_description>ABSSSI Efficacy Safety Tedizolid Phosphate Linezolid</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Males female &gt; /=18 year old Adequate venous access minimum 2 I.V . dos study drug Acute Bacterial Skin skin structure infection ( ABSSSI ) meeting least 1 clinical syndrome definition list require I.V . antibiotic therapy . Local symptom must start within 7 day Screening Visit Cellulitis/erysipelas Major cutaneous abscess Wound Infection Suspected document grampositive infection baseline Gram stain culture . Uncomplicated skin skin structure infection furuncle , minor abscess Infections associate , close proximity , prosthetic device Severe sepsis septic shock Known bacteremia time screen ABSSSI due associate following : Suspected document gramnegative pathogen patient cellulitis/erysipelas major cutaneous abscess require antibiotic specific gramnegative coverage . Patients wound infection gramnegative adjunctive therapy warrant may enrol meet eligibility criterion Diabetic foot infection , gangrene , perianal abscess Concomitant infection another site include secondary ABSSSI lesion ( eg , septic arthritis , endocarditis , osteomyelitis ) Infected burn Decubitus chronic skin ulcer , ischemic ulcer due peripheral vascular disease ( arterial venous ) Any evolve necrotizing process ( ie , necrotizing fasciitis ) Use antibiotic follow : Systemic antibiotic grampositive cocci activity treatment infection within 24 hour first infusion study drug Patients fail prior therapy primary infection site also exclude enrollment Topical antibiotic primary lesion within 24 hour first infusion study drug except antibiotic/antisepticcoated dress applied clean postsurgical wound Administration Linezolid within 30 day first infusion study drug Recent history opportunistic infection underlie cause infection still active ( eg , leukemia , transplant , acquire immunodeficiency syndrome [ AIDS ] ) Previous exposure Tedizolid Phosphate treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>